Bohring–Opitz syndrome

From WikiMD's Medical Encyclopedia

Revision as of 06:05, 20 February 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Bohring–Opitz Syndrome (BOS) is a rare genetic disorder characterized by distinctive facial features, growth delays, intellectual disability, and various physical abnormalities. It was first described by Axel Bohring and others in 1999. The syndrome is caused by mutations in the ASXL1 gene.

Symptoms and Signs

The symptoms of Bohring–Opitz Syndrome vary among affected individuals. Common symptoms include:

  • Distinctive facial features such as prominent eyes, a small nose with upturned nostrils, and a wide mouth with downturned corners.
  • Growth delays, including severe feeding difficulties, failure to thrive, and slow growth.
  • Intellectual disability, which is usually severe.
  • Physical abnormalities, including skeletal abnormalities, heart defects, and increased risk of Wilms tumor.

Causes

Bohring–Opitz Syndrome is caused by mutations in the ASXL1 gene. This gene provides instructions for making a protein that is involved in regulating other genes. Mutations in the ASXL1 gene disrupt the normal development of many parts of the body, leading to the features of Bohring–Opitz Syndrome.

Diagnosis

Diagnosis of Bohring–Opitz Syndrome is based on the presence of characteristic clinical features. Genetic testing can confirm the diagnosis by identifying a mutation in the ASXL1 gene.

Treatment

There is currently no cure for Bohring–Opitz Syndrome. Treatment is supportive and based on the symptoms in each individual. This may include feeding support, physical therapy, and management of any other medical conditions.

See Also

References

  • Bohring A, Silengo M, Lerone M, Superneau DW, Spaich C, Braddock SR, Poss A, Opitz JM. Severe end of Opitz trigonocephaly (C) syndrome or new syndrome? Am J Med Genet. 1999 Aug 27;85(5):438-46. doi: 10.1002/(sici)1096-8628(19990827)85:5<438::aid-ajmg3>3.0.co;2-6. PMID: 10440833.
  • Hoischen A, van Bon BW, Rodríguez-Santiago B, Gilissen C, Vissers LE, de Vries P, Janssen I, van Lier B, Hastings R, Smithson SF, Newbury-Ecob R, Kjaergaard S, Goodship J, McGowan R, Bartholdi D, Rauch A, Peippo M, Cobben JM, Wieczorek D, Gillessen-Kaesbach G, Veltman JA, Brunner HG, de Vries BB. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet. 2011 Aug;43(8):729-31. doi: 10.1038/ng.868. Epub 2011 Jul 3. PMID: 21725329; PMCID: PMC3738812.
This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.